Intercept Pharmaceuticals Inc (ICPT)

155.95
2.30 1.40
NASDAQ : Health Care
Prev Close 158.20
Open 157.78
Day Low/High 155.29 / 158.78
52 Wk Low/High 89.76 / 285.00
Volume 143.53K
Avg Volume 518.60K
Exchange NASDAQ
Shares Outstanding 24.60M
Market Cap 3.77B
EPS -9.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

Barbarian At The Gate: Intercept Pharmaceuticals (ICPT)

Barbarian At The Gate: Intercept Pharmaceuticals (ICPT)

Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Intercept Pharmaceuticals (ICPT): Today's Weak On High Volume Stock

Intercept Pharmaceuticals (ICPT): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a weak on high relative volume candidate

Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's

Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's Post-Market Leader Stock

Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a post-market leader candidate

Here's Why Intercept Pharma (ICPT) Stock Is Gaining Today

Here's Why Intercept Pharma (ICPT) Stock Is Gaining Today

Intercept Pharma (ICPT) stock is higher in mid-afternoon trading after the company's treatment for chronic liver disease received accelerated FDA approval.

Heavy Trading On Intercept Pharmaceuticals (ICPT) Before Market Open

Heavy Trading On Intercept Pharmaceuticals (ICPT) Before Market Open

Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a pre-market mover with heavy volume candidate

Investors Eager for Gilead to Make Big Moves

Investors Eager for Gilead to Make Big Moves

Jim Cramer likes Gilead but says investors are waiting for the biopharmaceutical company to make a more transformative move.

Gilead (GILD) Shares Spike After Executive Board Appointment

Gilead (GILD) Shares Spike After Executive Board Appointment

Analysts say the drugmaker is a good investment for short-term buyers or those who bet on risk.

Biotech Is Ripe for M&A: Analysts

After an asset price drop, large pharmaceutical companies are looking for strategic purchases.

Insider Trading Alert - ACTG, RNR And ICPT Traded By Insiders

Insider Trading Alert - ACTG, RNR And ICPT Traded By Insiders

Stocks with insider trader activity include ACTG, RNR and ICPT

Intercept Pharma (ICPT) Stock Slips, Downgraded at Morgan Stanley

Intercept Pharma (ICPT) Stock Slips, Downgraded at Morgan Stanley

Intercept Pharma (ICPT) stock is falling on Friday afternoon as Morgan Stanley downgraded the company to ‘underweight.’

Intercept Seen As Takeover Target, But Morgan Stanley Says Sell

Intercept Seen As Takeover Target, But Morgan Stanley Says Sell

Yesterday, an FDA advisory committee voted unanimously to recommend approval of Intercept Pharmaceuticals' Ocaliva, which sparked positive comments from several analysts.

Intercept Pharmaceuticals (ICPT) Leads The Pack In Pre-Market Activity

Intercept Pharmaceuticals (ICPT) Leads The Pack In Pre-Market Activity

Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a pre-market leader candidate

Insider Trading Alert - ICPT, FMNB And TIPT Traded By Insiders

Insider Trading Alert - ICPT, FMNB And TIPT Traded By Insiders

Stocks with insider trader activity include ICPT, FMNB and TIPT

Why Intercept Pharmaceuticals (ICPT) Stock is Spiking Today

Why Intercept Pharmaceuticals (ICPT) Stock is Spiking Today

Intercept Pharmaceuticals (ICPT) stock is rising on Tuesday as the FDA’s staff reviewers supported the use of its liver drug for patients who didn’t respond to the standard of care.

Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's

Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate